Free Trial
NASDAQ:TENX

Tenax Therapeutics Q4 2024 Earnings Report

Tenax Therapeutics logo
$5.91 -0.07 (-1.17%)
Closing price 04:00 PM Eastern
Extended Trading
$5.90 -0.02 (-0.25%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tenax Therapeutics EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.52
Beat/Miss
Beat by +$0.34
One Year Ago EPS
N/A

Tenax Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tenax Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 25, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Tenax Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Wednesday, August 13, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Tenax Therapeutics Earnings Headlines

TENX Tenax Therapeutics, Inc. - Seeking Alpha
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Tenax Therapeutics Inc.
See More Tenax Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email.

About Tenax Therapeutics

Tenax Therapeutics (NASDAQ:TENX) develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

View Tenax Therapeutics Profile

More Earnings Resources from MarketBeat